Anastomotic leakage and functional outcomes following total mesorectal excision with delayed and immediate colo-anal anastomosis for rectal cancer: Two single-arm phase II trials.


Journal

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
ISSN: 1532-2157
Titre abrégé: Eur J Surg Oncol
Pays: England
ID NLM: 8504356

Informations de publication

Date de publication:
Nov 2023
Historique:
received: 31 03 2023
revised: 31 07 2023
accepted: 10 08 2023
medline: 13 11 2023
pubmed: 11 11 2023
entrez: 10 11 2023
Statut: ppublish

Résumé

Anastomotic leakage (AL) remains a major cause of morbidity following total mesorectal excision (TME). A diverting ileostomy reduces the risk of AL but impairs quality of life (QoL). Delayed colo-anal anastomosis (DCAA) may be an alternative to immediate colo-anal anastomosis (ICAA) without creation of a diverting ileostomy. Patients with T3 or N+ rectal tumours were treated with neoadjuvant chemoradiation and TME. To evaluate DCAA or ICAA with diverting ileostomy, a two multicenter single-arm phase II trials was designed. The primary endpoint was the rate of AL requiring a diverting ileostomy up to 30 days postoperatively. Secondary endpoints were 30-day postoperative complications, 1- and 2-year disease-free survival; QoL at baseline, 6 months and anorectal function measured by the low anterior resection syndrome questionnaire and Wexner score at baseline, 6 months and a late assessment at median 8 years following surgery. AL requiring diverting ileostomy occurred in one patient (2.1%; 95% confidence interval (CI) [0; 11.1]) in the DCAA group and in five patients (8.6%; 95%CI [3.2; 21.0]) in the ICAA group. Thirty-day postoperative complications occurred in 13 patients (27.1%) in the DCAA group and in 10 patients (19.2%) in the ICAA group. Short and long-term functional outcomes showed similar patterns. These two single-arm phase II trials showed that DCAA has low rates of AL requiring a diverting ileostomy and acceptable long-term functional results. DCAA seems a good choice to restore bowel continuity.

Sections du résumé

BACKGROUND BACKGROUND
Anastomotic leakage (AL) remains a major cause of morbidity following total mesorectal excision (TME). A diverting ileostomy reduces the risk of AL but impairs quality of life (QoL). Delayed colo-anal anastomosis (DCAA) may be an alternative to immediate colo-anal anastomosis (ICAA) without creation of a diverting ileostomy.
STUDY DESIGN METHODS
Patients with T3 or N+ rectal tumours were treated with neoadjuvant chemoradiation and TME. To evaluate DCAA or ICAA with diverting ileostomy, a two multicenter single-arm phase II trials was designed. The primary endpoint was the rate of AL requiring a diverting ileostomy up to 30 days postoperatively. Secondary endpoints were 30-day postoperative complications, 1- and 2-year disease-free survival; QoL at baseline, 6 months and anorectal function measured by the low anterior resection syndrome questionnaire and Wexner score at baseline, 6 months and a late assessment at median 8 years following surgery.
RESULTS RESULTS
AL requiring diverting ileostomy occurred in one patient (2.1%; 95% confidence interval (CI) [0; 11.1]) in the DCAA group and in five patients (8.6%; 95%CI [3.2; 21.0]) in the ICAA group. Thirty-day postoperative complications occurred in 13 patients (27.1%) in the DCAA group and in 10 patients (19.2%) in the ICAA group. Short and long-term functional outcomes showed similar patterns.
CONCLUSION CONCLUSIONS
These two single-arm phase II trials showed that DCAA has low rates of AL requiring a diverting ileostomy and acceptable long-term functional results. DCAA seems a good choice to restore bowel continuity.

Identifiants

pubmed: 37949519
pii: S0748-7983(23)00653-4
doi: 10.1016/j.ejso.2023.107015
pii:
doi:

Types de publication

Clinical Trial, Phase II Multicenter Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

107015

Informations de copyright

© 2023 Published by Elsevier Ltd.

Déclaration de conflit d'intérêts

Declaration of competing interest Do not declare any conflict of interest.

Auteurs

Serge Evrard (S)

Digestive Tumors Unit, Institut Bergonié, Comprehensive Cancer Center, F-33000, Bordeaux, France; Univ. Bordeaux, Bordeaux, France; INSERM U1312-BRIC, Pessac, France. Electronic address: s.evrard@bordeaux.unicancer.fr.

Carine Bellera (C)

Univ. Bordeaux, INSERM, Bordeaux Population Health Research Center, Epicene Team, UMR 1219, F-33000, Bordeaux, France; Clinical & Epidemiological Research Unit, INSERM CIC1401, Comprehensive Cancer Center, F-33000 Institut Bergonié, Bordeaux, France.

Gregoire Desolneux (G)

Digestive Tumors Unit, Institut Bergonié, Comprehensive Cancer Center, F-33000, Bordeaux, France.

Coralie Cantarel (C)

Clinical & Epidemiological Research Unit, INSERM CIC1401, Comprehensive Cancer Center, F-33000 Institut Bergonié, Bordeaux, France.

Emilie Toulza (E)

Clinical & Epidemiological Research Unit, INSERM CIC1401, Comprehensive Cancer Center, F-33000 Institut Bergonié, Bordeaux, France.

Jean-Luc Faucheron (JL)

CHU de Grenoble, La Tronche, France.

Michel Rivoire (M)

Department of Surgical Oncology, Centre Léon Bérard, Comprehensive Cancer Center, Lyon, France.

Aurélien Dupré (A)

Department of Surgical Oncology, Centre Léon Bérard, Comprehensive Cancer Center, Lyon, France.

Jean-Yves Mabrut (JY)

Centre Hospitalier Universitaire de Lyon, Lyon, France.

Laurent Bresler (L)

Centre Hospitalier Universitaire de Nancy, Vandœuvre-lès-Nancy, France.

Frédéric Marchal (F)

Department of Surgical Oncology, Institut de Cancérologie de Lorraine, Comprehensive Cancer Center, Vandœuvre-lès-Nancy, France.

Damien Bouriez (D)

Department of Colorectal Surgery, Centre Hospitalier Universitaire de Bordeaux, Centre Magellan, Pessac, France.

Eric Rullier (E)

Univ. Bordeaux, Bordeaux, France; Department of Colorectal Surgery, Centre Hospitalier Universitaire de Bordeaux, Centre Magellan, Pessac, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH